{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:01:56Z","timestamp":1791655316921,"version":"4.3.4"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI114617-01A1"],"award-info":[{"award-number":["AI114617-01A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["U54GM088558"],"award-info":[{"award-number":["U54GM088558"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Morris-Singer Foundation"},{"name":"Department of Health and Social Care"},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000278","name":"Department for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine evaluation, could reduce the global burden of coronavirus-related mortality and morbidity. Volunteers in such studies could autonomously authorize the risks to themselves, and their net risk could be acceptable if participants comprise healthy young adults, who are at relatively low risk of serious disease following natural infection, if they have a high baseline risk of natural infection, and if during the trial they receive frequent monitoring and, following any infection, the best available care.<\/jats:p>","DOI":"10.1093\/infdis\/jiaa152","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T03:30:29Z","timestamp":1585625429000},"page":"1752-1756","source":"Crossref","is-referenced-by-count":198,"title":["Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure"],"prefix":"10.1093","volume":"221","author":[{"given":"Nir","family":"Eyal","sequence":"first","affiliation":[{"name":"Center for Population-Level Bioethics, Rutgers University, New Brunswick, New Jersey, USA"},{"name":"Department of Philosophy, Rutgers University, New Brunswick, New Jersey, USA"},{"name":"Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1504-9213","authenticated-orcid":false,"given":"Marc","family":"Lipsitch","sequence":"first","affiliation":[{"name":"Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA"},{"name":"Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G","family":"Smith","sequence":"first","affiliation":[{"name":"MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"2020051111583387500_CIT0001","author":"World Health Organization"},{"key":"2020051111583387500_CIT0002","article-title":"When will a coronavirus vaccine be ready?","author":"Spinney","year":"17","journal-title":"Guardian"},{"key":"2020051111583387500_CIT0003","author":"Centers for Disease Control and Prevention"},{"key":"2020051111583387500_CIT0004","article-title":"Who is getting sick, and how sick? A breakdown of coronavirus risk by demographic factors","author":"Begley","year":"3","journal-title":"STATnews"},{"key":"2020051111583387500_CIT0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.46234\/ccdcw2020.032","article-title":"Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)\u2014China, 2020","volume":"2","author":"Novel Coronavirus Pneumonia Emergency Response Epidemiology Team","year":"2020","journal-title":"CCDC Weekly"},{"key":"2020051111583387500_CIT0006","first-page":"20028423","article-title":"Epidemiology and transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts","author":"Bi","year":"3","journal-title":"medRxiv"},{"key":"2020051111583387500_CIT0007","article-title":"Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding","author":"Xu","journal-title":"Nat Med"},{"key":"2020051111583387500_CIT0008","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fcimb.2019.00107","article-title":"The future of flu: a review of the human challenge model and systems biology for advancement of influenza vaccinology","volume":"9","author":"Sherman","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"2020051111583387500_CIT0009","doi-asserted-by":"crossref","first-page":"e02015-19","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"2020051111583387500_CIT0010","volume-title":"The global impact of COVID-19 and strategies for mitigation and suppression.","author":"Walker","year":"2020"},{"key":"2020051111583387500_CIT0011","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:osobl\/9780199896202.001.0001","volume-title":"The ethical challenges of human research: selected essays, 1st ed","author":"Miller","year":"2012"},{"key":"2020051111583387500_CIT0012","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/COH.0000000000000489","article-title":"Ethical issues in HIV remission trials","volume":"13","author":"Eyal","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"2020051111583387500_CIT0013","article-title":"Studies that intentionally infect people with disease-causing bugs are on the rise","volume-title":"Science","author":"Cohen","year":"2016"},{"key":"2020051111583387500_CIT0014","article-title":"Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals","author":"Boodman","year":"11","journal-title":"STATnews"},{"key":"2020051111583387500_CIT0015","volume-title":"Ethical considerations for Zika virus human challenge trials","author":"Shah","year":"2017"},{"key":"2020051111583387500_CIT0016","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/jiz173","article-title":"Risk to nonparticipants in HIV remission studies with treatment interruption: a symposium","volume":"220(","author":"Eyal","year":"2019","journal-title":"J Infect Dis"},{"key":"2020051111583387500_CIT0017","volume-title":"Impact of non-pharmaceutical interventions (NPIs) to reduce COVID- 19 mortality and healthcare demand","author":"Ferguson","year":"2020"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa152\/33031978\/jiaa152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/11\/1752\/33202415\/jiaa152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/11\/1752\/33202415\/jiaa152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T17:59:10Z","timestamp":1615053550000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/221\/11\/1752\/5814216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":17,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,3,31]]},"published-print":{"date-parts":[[2020,5,11]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa152","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6,1]]},"published":{"date-parts":[[2020,3,31]]}}}